Questions: With respect to BRAF V600E testing: A. A positive BRAF V600E test by immunohistochemistry can be used to decide therapy with BRAF inhibitors in patients with advanced melanoma B. There is a significant discrepancy between immunohistochemistry and molecular testing C. The immunohistochemical test needs to be reported according to a specific scoring system D. The immunohistochemical test shows low specificity and sensitivity

With respect to BRAF V600E testing:
A. A positive BRAF V600E test by immunohistochemistry can be used to decide therapy with BRAF inhibitors in patients with advanced melanoma
B. There is a significant discrepancy between immunohistochemistry and molecular testing
C. The immunohistochemical test needs to be reported according to a specific scoring system
D. The immunohistochemical test shows low specificity and sensitivity
Transcript text: With respect to BRAF V600E testing: A. A positive BRAF V600E test by immunohistochemistry can be used to decide therapy with BRAF inhibitors in patients with advanced melanoma B. There is a significant discrepancy between immunohistochemistry and molecular testing C. The immunohistochemical test needs to be reported according to a specific scoring system D. The immunohistochemical test shows low specificity and sensitivity
failed

Solution

failed
failed

The answer is the first one (A): A positive BRAF V600E test by immunohistochemistry can be used to decide therapy with BRAF inhibitors in patients with advanced melanoma.

Explanation for each option:

A. A positive BRAF V600E test by immunohistochemistry can be used to decide therapy with BRAF inhibitors in patients with advanced melanoma.

  • This statement is correct. Immunohistochemistry (IHC) can be used to detect the presence of the BRAF V600E mutation, which is a common mutation in melanoma. If the test is positive, it can guide the use of BRAF inhibitors as a targeted therapy for patients with advanced melanoma.

B. There is a significant discrepancy between immunohistochemistry and molecular testing.

  • This statement is incorrect. While there can be some discrepancies between IHC and molecular testing, they are generally considered complementary. IHC is a quicker and less expensive method, but molecular testing (such as PCR or sequencing) is more definitive.

C. The immunohistochemical test needs to be reported according to a specific scoring system.

  • This statement is incorrect. While IHC results are often reported with some form of scoring or qualitative assessment, there is no universally mandated specific scoring system for BRAF V600E testing.

D. The immunohistochemical test shows low specificity and sensitivity.

  • This statement is incorrect. IHC for BRAF V600E has been shown to have high specificity and sensitivity, making it a reliable method for detecting this mutation in clinical practice.

Summary: The correct answer is A. A positive BRAF V600E test by immunohistochemistry can be used to decide therapy with BRAF inhibitors in patients with advanced melanoma. This method is reliable and can guide targeted therapy decisions.

Was this solution helpful?
failed
Unhelpful
failed
Helpful